Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status

M. Z. Gilcrease

Research output: Contribution to journal › Comment/debate › peer-review

Fingerprint

Dive into the research topics of 'Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status'. Together they form a unique fingerprint.